MedTrace Logo

Effectiveness of Tofacitinib in Systemic Sclerosis

NCT06044844 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-09-21

No results posted yet for this study

Summary

The goal of this clinical trial is to compare efficacy of tofacitinib with cyclophosphamide in skin thickening in early diffuse cutaneous systemic sclerosis .

Conditions

  • Efficacy of Tofacitinib in the Systemic Sclerosis

Interventions

DRUG

Tofacitinib

tofacitinib efficacy

Sponsors & Collaborators

  • Aristopharma Ltd

    collaborator INDUSTRY

  • Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    lead OTHER

Principal Investigators

  • Nabil Khan, MBBS · resident

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06044844 on ClinicalTrials.gov